Status:
COMPLETED
Efficacy and Safety of Ruxolitinib in Patients With Myelofibrosis
Lead Sponsor:
Qilu Hospital of Shandong University
Conditions:
Myelofibrosis
Eligibility:
All Genders
18+ years
Brief Summary
Ruxolitinib is a Janus kinase (JAK) 1/2 inhibitor currently used in the treatment of Myelofibrosis (MF). Ruxolitinib confirmed improvements in splenomegaly, MF-related symptoms and survival benefit in...
Eligibility Criteria
Inclusion
- Male or female patients aged ≥18 years with a diagnosis of primary or secondary MF by World Health Organization and International Working Group for Myeloproliferative Neoplasms Research and Treat- ment (IWG-MRT) criteria;
- Received ruxolitinib treatment for ≥3 months.
Exclusion
- Malignant tumors with other progression or myelofibrosis secondary to other diseases;
- Exclude myelofibrosis patients after splenectomy;
- Patients with poor compliance with case follow-up or lost to follow-up.
Key Trial Info
Start Date :
August 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2021
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT05410470
Start Date
August 1 2012
End Date
December 1 2021
Last Update
June 8 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.